US3274056A - Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate - Google Patents

Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate Download PDF

Info

Publication number
US3274056A
US3274056A US432376A US43237665A US3274056A US 3274056 A US3274056 A US 3274056A US 432376 A US432376 A US 432376A US 43237665 A US43237665 A US 43237665A US 3274056 A US3274056 A US 3274056A
Authority
US
United States
Prior art keywords
sulfate
methoxyestra
trien
alkali metal
lowering blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US432376A
Inventor
Cantrall Edward Warren
Littell Ruddy
Bernstein Seymour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US432376A priority Critical patent/US3274056A/en
Application granted granted Critical
Publication of US3274056A publication Critical patent/US3274056A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone

Definitions

  • M is an alkali metal
  • the invention relates to compositions containing alkali metal salts of 2-methoxyestra-1,3,5(l0)-trien-3-ol-17-one sulfates and edible carrier.
  • alkali metal salts are white crystalline solids, soluble in water, partly soluble in polar organic solvents such as methanol, and generally insoluble in non-polar organic solvents such as benzene, diethyl ether, petroleum ether and the like.
  • the active components of this invention may be prepared, for example, by reacting Z-methoxyestrone with a sulfating agent such as chlorosulfonic acid or ethyl chlorosulfonate.
  • a sulfating agent such as chlorosulfonic acid or ethyl chlorosulfonate.
  • the reaction is ordinarily carried out in an inert organic solvent such as methylene chloride in the presence of a base such as pyridine.
  • the resulting pyridinium salt may be dissolved in methanol and converted into the desired salt by neutralization with sodium hydroxide or the like.
  • the compounds of this invention may also be prepared, for example, by reacting 2-methoxyestrone with a sulfating agent such as sulfamic acid.
  • a sulfating agent such as sulfamic acid.
  • the reaction is ordinarily carried out in the presence of a base such as pyridine.
  • the resulting pyridinium salt may be converted into the desired salt by neutralization with sodium hydroxide, potassium hydroxide or the like.
  • the steroid components described above may be dispensed as the active ingredient in compositions of the steroid and an edible carrier. While the amount of steroid to be given daily will depend on many factors such as size, weight, age, etc., of the warm-blooded animal, it has been found, for example, that a daily intake of from 1 mg. to 10 mg. of body weight will produce good results.
  • the dosage unit may be in a form for a single unit per day, or smaller forms for use as multiple units per day. In the case of tablets, they may be of larger size, scored for use as fractional units one or more times per day.
  • compositions can be dispensed in the form of soft or hard shell gelatin capsules.
  • diluents such as lactose, starch, magnesium oxide, magnesium stearate and the like.
  • the capsules may be large enough to provide the desirable daily dosage to be used in multiple doses per day.
  • compositions may be dispensed as parenteral solutions or suspensions. If larger doses in small amounts are desirable it may be necessary to use parenteral suspensions because the solubility of the steroids in substantially aqueous solutions is limited.
  • compositions using the salts of the present invention as the active component may take the form of syrups or pediatric drops.
  • Such formulations usually contain one or more of the following suspending agents, buffer salts, stabilizers, preservatives and the like.
  • the steroid compounds of this invention are effective in lowering blood cholesterol in animal tests and are therefore useful in treating hypercholesteremia.
  • Example 1 Preparation of sodium Z-methoxyeslra- 1,3,5(10) -trz'en-3-0l-17-one sulfate (sodium Z-methoxyestrone sulfate)
  • sodium Z-methoxyestrone sulfate sodium Z-methoxyestrone sulfate
  • a solution containing 1.35 g. of Z-methoxyestrone in a mixture of 20 ml. of pyridine and 40 ml. of methylene chloride To the above solution is added a solution containing 1.35 g. of Z-methoxyestrone in a mixture of 20 ml. of pyridine and 40 ml. of methylene chloride. The resulting mixture is allowed to stand at room temperature for three
  • the mixture is filtered and the filtrate is concentrated to about 20 ml. Ether (ca. ml.) is added and the mixture is cooled.
  • the pyridinium salt (410 mg., melting point 205209 C.) precipitates, is filtered, suspended in methanol and is neutralized with 1 N sodium hydroxide in methanol.
  • the resulting turbid solution is filtered and diluted with about 200 ml. of ether.
  • the product precipitates as an amorphous white powder, 400 mg. (20% melting point 175 C.
  • Example II Following the procedure of Example I and neutralizing the pyridinium salt with potassium hydroxide solution produces potassium 2-methoxyestra-1,3,5(l0)-trien- 3-ol-17-one sulfate.
  • the solid material is mixed well with the ether and then collected by filtration.
  • the solid is washed twice with anhydrous ether (5 ml. each time) and dried in vacuo over phosphorous pentoxide at room temperature for /2 hour.
  • the solid (wt. 1.16 g.) is ground in a mortar and added to a mixture of 8 ml. of 12% aqueous potassium hydroxide and 4 ml. of pyridine. After mixing thoroughly, the organic layer is separated and filtered to remove traces of solid.
  • the solid and mixing vessel are Washed twice with 0.5 ml. of pyridine which is added to the filtrate. To the filtrate is added 25 ml.
  • a method of lowering blood cholesterol in warmblooded animals which comprises administering to said animal from 1 mg. to 10 mgs. per kg. of body weight of an alkali metal 2-rnethoxyestra-l,3,5(10)-trien3-ol-17- one sulfate.
  • a method of lowering blood cholesterol in warmblooded animals which comprises administering to said animals from 1 mg. to 10 mgs. per kg. of body weight of potassium 2-methoxyestra-1,3,5 l0)-trien-3-ol-1'7-one sulfate.
  • a method of lowering blood cholesterol in warmblooded animals which comprises administering to said animals from 1 mg. to 10 mgs. per kg. of body weight of sodium 2-methoxyestra-1,3,5 (10)-trien-3-ol-17-one sulfate.
  • a therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which cornprises from 1 mg. to 10 mgs. per kg. of body Weight of an alkali metal 2-methoxyestra-1,3,5(10)-trien-3-ol-17-one sulfate and an edible carrier.
  • a therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which comprises from 1 mg. to 10 mgs. per kg. of body weight of potassium 2-methoxyestra-1,3,5 (10)-trien-3-ol-17-one sulfate and an edible carrier.
  • a therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which comprises from 1 mg. to 10 mgs. per kg. of body weight of sodium 2-methoxyestra-1,3,5(10)-trien-3-ol-17-one sulfate and an edible carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent 3,274,056 METHODS FOR LOWERING BLOOD CHOLESTER- OL AND COMPOSITIONS 0F ALKALI METAL 2- METHOXYESTRA 1,3,5()-TRIEN-3-0L-17-0NE SULFATE Edward Warren Cantrall, New City, N.Y., Ruddy Littell, Rivervale, N.J., and Seymour Bernstein, New City, .Y., assignors to American Cyanamid Company, Stamford, Conn., a corporation of Maine No Drawing. Filed Feb. 12, 1965, Ser. No. 432,376
6 Claims. (Cl. 167-65) be illustrated by the following formula:
wherein M is an alkali metal.
The invention relates to compositions containing alkali metal salts of 2-methoxyestra-1,3,5(l0)-trien-3-ol-17-one sulfates and edible carrier. These alkali metal salts are white crystalline solids, soluble in water, partly soluble in polar organic solvents such as methanol, and generally insoluble in non-polar organic solvents such as benzene, diethyl ether, petroleum ether and the like.
The active components of this invention may be prepared, for example, by reacting Z-methoxyestrone with a sulfating agent such as chlorosulfonic acid or ethyl chlorosulfonate. The reaction is ordinarily carried out in an inert organic solvent such as methylene chloride in the presence of a base such as pyridine. The resulting pyridinium salt may be dissolved in methanol and converted into the desired salt by neutralization with sodium hydroxide or the like.
The compounds of this invention may also be prepared, for example, by reacting 2-methoxyestrone with a sulfating agent such as sulfamic acid. The reaction is ordinarily carried out in the presence of a base such as pyridine. The resulting pyridinium salt may be converted into the desired salt by neutralization with sodium hydroxide, potassium hydroxide or the like.
The steroid components described above may be dispensed as the active ingredient in compositions of the steroid and an edible carrier. While the amount of steroid to be given daily will depend on many factors such as size, weight, age, etc., of the warm-blooded animal, it has been found, for example, that a daily intake of from 1 mg. to 10 mg. of body weight will produce good results. The dosage unit may be in a form for a single unit per day, or smaller forms for use as multiple units per day. In the case of tablets, they may be of larger size, scored for use as fractional units one or more times per day.
The compositions can be dispensed in the form of soft or hard shell gelatin capsules. Also present in the capsules may be diluents such as lactose, starch, magnesium oxide, magnesium stearate and the like. The capsules may be large enough to provide the desirable daily dosage to be used in multiple doses per day.
The present compositions may be dispensed as parenteral solutions or suspensions. If larger doses in small amounts are desirable it may be necessary to use parenteral suspensions because the solubility of the steroids in substantially aqueous solutions is limited.
Compositions using the salts of the present invention as the active component may take the form of syrups or pediatric drops. Such formulations: usually contain one or more of the following suspending agents, buffer salts, stabilizers, preservatives and the like.
The steroid compounds of this invention are effective in lowering blood cholesterol in animal tests and are therefore useful in treating hypercholesteremia.
The following tested were conducted male rats, C.F.E. strain, l20140 g. initial weight, obtained from Carworth Farms, New City, New York, in a group of four was fed the compound incorporated in the diet at a 0.005% dose level for 6 days. By a heart puncture technique serum blood samples were obtained and cholesterol levels.
were determined by the Leffier procedure (Amer. J. Clin. Path, 31, 310 (1959)).
An estrogenic assay (three-day assay) was performed in the intact immature female rat (4060 g. Sherman strain) essentially according to B. L. Rubin et al, Endocrinology, 49, 429 (1951). The following table summarizes the above testing results:
The following example describe the compounds of the present invention.
Example 1 .Preparation of sodium Z-methoxyeslra- 1,3,5(10) -trz'en-3-0l-17-one sulfate (sodium Z-methoxyestrone sulfate) To an ice cold solution of 1.0 ml. of chlorosulfonic acid in 20 ml. of methylene chloride is added dropwise, with swirling, 15 ml. of pyridine. To the above solution is added a solution containing 1.35 g. of Z-methoxyestrone in a mixture of 20 ml. of pyridine and 40 ml. of methylene chloride. The resulting mixture is allowed to stand at room temperature for three'days. The mixture is filtered and the filtrate is concentrated to about 20 ml. Ether (ca. ml.) is added and the mixture is cooled. The pyridinium salt (410 mg., melting point 205209 C.) precipitates, is filtered, suspended in methanol and is neutralized with 1 N sodium hydroxide in methanol. The resulting turbid solution is filtered and diluted with about 200 ml. of ether. The product precipitates as an amorphous white powder, 400 mg. (20% melting point 175 C.
Example II Following the procedure of Example I and neutralizing the pyridinium salt with potassium hydroxide solution produces potassium 2-methoxyestra-1,3,5(l0)-trien- 3-ol-17-one sulfate.
In a similar manner the other alkali metal salts are prepared.
Example IlI.--Preparatin 0 Potassium 3-hydroxy-2- methoxyestra-1,3,5(10) -trien-17-0ne sulfate (potassium Z-methoxyestrone sulfate) In a 2 ml. of pyridine (reagent grade) there is dissolved 500 mg. of 2-methoxyestrone and the solution is warmed in an oil bath (8595 C.) with stirring. To this is added 540 mg. of pulverized sulfamic acid. The mixture is heated at 8595 C. for 2 hours with continued stirring and is then cooled at room temperature. To the cooled mixture is added ml. of anhydrous ether, the solid material is mixed well with the ether and then collected by filtration. The solid is washed twice with anhydrous ether (5 ml. each time) and dried in vacuo over phosphorous pentoxide at room temperature for /2 hour. The solid (wt. 1.16 g.) is ground in a mortar and added to a mixture of 8 ml. of 12% aqueous potassium hydroxide and 4 ml. of pyridine. After mixing thoroughly, the organic layer is separated and filtered to remove traces of solid. The solid and mixing vessel are Washed twice with 0.5 ml. of pyridine which is added to the filtrate. To the filtrate is added 25 ml. of anhydrous ether and the resulting solid is separated from the ether by decantation and washed three times with m1. portion of anhydrous ether. To the residue is added 100 ml. of 95% ethyl alcohol (95 ml. absolute ethyl alcohol, 5 ml. water) and the solution is treated with charcoal while boiling and filtered while hot through diatomaceous earth. Upon cooling a white crystalline solid gradually separates and crystallization is completed overnight at 5 C. The solid is collected, washed with cold absolute ethanol and dried at room temperature over fresh phosphorus pentoxide at 0.5 mm. for 24 hours. There is obtained 470 mg. of a white crystalline solid, melting point ca. ZOO-250 C. dec. (66% yield).
Analysis.-Calcd. for C H O SK- /2H O: C, 53.38; H, 5.66; S, 7.50; K, 9.15, K.F., 2.11. Found: C, 52.89, 53.00; H, 5.79, 5.60; S, 7.35, 7.75; K, 9.18, 9.03; K.F., 2.15, K.F., 2.01.
S (gr-avimetric) Kl (Karl Fischer H20 determination) We claim:
1. A method of lowering blood cholesterol in warmblooded animals which comprises administering to said animal from 1 mg. to 10 mgs. per kg. of body weight of an alkali metal 2-rnethoxyestra-l,3,5(10)-trien3-ol-17- one sulfate.
2. A method of lowering blood cholesterol in warmblooded animals which comprises administering to said animals from 1 mg. to 10 mgs. per kg. of body weight of potassium 2-methoxyestra-1,3,5 l0)-trien-3-ol-1'7-one sulfate.
3. A method of lowering blood cholesterol in warmblooded animals which comprises administering to said animals from 1 mg. to 10 mgs. per kg. of body weight of sodium 2-methoxyestra-1,3,5 (10)-trien-3-ol-17-one sulfate.
4. A therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which cornprises from 1 mg. to 10 mgs. per kg. of body Weight of an alkali metal 2-methoxyestra-1,3,5(10)-trien-3-ol-17-one sulfate and an edible carrier.
5. A therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which comprises from 1 mg. to 10 mgs. per kg. of body weight of potassium 2-methoxyestra-1,3,5 (10)-trien-3-ol-17-one sulfate and an edible carrier.
6. A therapeutic composition effective in lowering blood cholesterol in warm-blooded animals which comprises from 1 mg. to 10 mgs. per kg. of body weight of sodium 2-methoxyestra-1,3,5(10)-trien-3-ol-17-one sulfate and an edible carrier.
No references cited.
JULIAN S. LEVITT, Primary Examiner.
VERA C. CLARKE, Examiner.

Claims (1)

1. A METHOD OF LOWERING BLOOD CHOLESTEROL IN WARMBLOODED ANIMALS WHICH COMPRISES ADMINISTERING TO SAID ANIMAL FROM 1 MG. TO 10 MGS. PER KG. OF BODY WEIGHT OF AN ALKALI METAL 2-METHOXYESTRA-1,3,5(10)-TRINE-3-OL-17ONE SULFATE.
US432376A 1963-05-17 1965-02-12 Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate Expired - Lifetime US3274056A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US432376A US3274056A (en) 1963-05-17 1965-02-12 Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28134363A 1963-05-17 1963-05-17
US432376A US3274056A (en) 1963-05-17 1965-02-12 Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate

Publications (1)

Publication Number Publication Date
US3274056A true US3274056A (en) 1966-09-20

Family

ID=26960840

Family Applications (1)

Application Number Title Priority Date Filing Date
US432376A Expired - Lifetime US3274056A (en) 1963-05-17 1965-02-12 Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate

Country Status (1)

Country Link
US (1) US3274056A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923376A1 (en) * 1996-05-09 1999-06-23 Amrad Operations Pty.,Ltd. Treatment of asthma and airway diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923376A1 (en) * 1996-05-09 1999-06-23 Amrad Operations Pty.,Ltd. Treatment of asthma and airway diseases
EP0923376A4 (en) * 1996-05-09 2001-09-26 Amrad Operations Pty Ltd Treatment of asthma and airway diseases

Similar Documents

Publication Publication Date Title
EP0242851A1 (en) N-(2'-aminophenyl)-benzamide derivatives, process for their manufacture and their application in the treatment of neoplastic illness
Berenbom et al. Biochemical studies of toxic agents. 3. The isolation of 1-and 2-naphthylsulphuric acid and 1-and 2-naphthylglucuronide from the urine of rats dosed with 1-and 2-naphthol
DE2710242A1 (en) 5-ANGLE CLAMP ON 1,1-DIPHENYL- 3- (5- OR 6-HYDROXY-2-AZABICYCLO ANGULAR CLAMP ON 2,2,2 ANGLE CLAMP FOR OCT-2-YL) PROPYL ANGLE CLAMP FOR -2- ALKYL- 1,3,4-OXADIAZOLES AND RELATED COMPOUNDS
US3266991A (en) Pharmaceutical preparations of 1-dehydro-testosterone undecyclenate
DE1244777B (en) Process for the production of 7alpha-methyl-16alpha-hydroxy-oestrone or -3, 16-diacetate
US3274056A (en) Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate
DE3741801A1 (en) 17-Methylene-estratrienes
DE1468311C3 (en) 6-chloro-4,6-pregnadiene-3beta-17 alpha-diol-20-one-17-acetate-3-methyl ether and processes for its production and pharmaceutical preparations containing them
DE3336292C2 (en)
DE2139516C3 (en) 3,4-Dihydroxybenzyl alcohol derivatives, their acid addition salts, processes for their preparation and pharmaceuticals
Ray et al. COMPOUNDS FOR CANCER RESEARCH. V. RADIOACTIVE SULFONAMIDES1
DE4330237C2 (en) 1-Methyl-substituted androsta-1,4-diene-3,17-diones, process for their preparation and pharmaceutical preparations containing them
US3629304A (en) 17alpha-alkynyl - 11beta 13beta - dialkylgona-1 3 5 (10)-triene - 3 17beta-diol 3-cycloalkyl ethers compositions and method
Sobotka et al. Urine extractives in cancer
EP0289451A1 (en) 3-Methylene-androst-4-en-17-ones, process for their preparation and pharmaceutical compositions containing them
DE2807611C2 (en)
Segal Introduction and history of gossypol
US3127314A (en) Method of reducing hyperlipemia by
DE2711516A1 (en) NEW 17-SPIROSULTIN DERIVATIVES, THE CORRESPONDING GAMMA HYDROXY ACIDS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINED
EP0213295A1 (en) Thieno-1,2-thiazole derivatives, process for their preparation, and pharmaceutical compositions containing them
US3334013A (en) Substituted 17beta-androst-4-en-3-one and 19-norandrost-4-en-3-one and method of preparing the same
DE1167340B (en) Process for the preparation of 3- (N-pyrrolidinyl) -steroids
DE2656574A1 (en) 1-Alkyl-4-oxo-1,4-di:hydro-1,6-naphthyridine-3-carboxylic acid derivs. - with antibacterial activity esp. effective in the urinary tract
DE2336107A1 (en) PHENOXYCARBONIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS
DE2037155A1 (en)